ADMA BIOLOGICS, INC.

ADMA
About the company

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.

Country: United StatesPrice: $13.68Market Cap: $3.0B

Investment snapshot

24%positive consensus
Scored 1d ago

Positive

3

BUY / PASS

Neutral / negative

4 / 9

NEUTRAL / FAIL

Median fair value

$4.71

-65.6% vs price

Models with upside

0 / 17

Positive margin of safety

Strongest signal

9 of 12 pass — Lynch, Akre and Asness object

Key risk

ADMA overvalued: all 8 models price fair value below $13.68 (median $4.71)

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILBUY · Rank #314 (Top 10.1%)NEUTRALPASSBUYFAILNEUTRALFAILBUYFAILNEUTRALFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of Safety-162.6%-91.9%N/A-249.9%N/A-113.8%-242.0%-33.1%N/AN/A-225.7%-936.4%N/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-02-25

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-02-25

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-02-25

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-04

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-04

Score computed: 2026-11-14

Where It Passes

  • Debt & Leverage75% pass✓ 11✗ 4▾

    9 of 12 pass — Lynch, Akre and Asness object

    Debt Levels0.45
    ✓MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    LT Debt vs Net Current AssetsLT Debt $191.6M vs NCA $480.6M
    ✓GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.45, IC: 22.8x
    ✓BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.45
    ✗Lynch< 0.33
    Cash - Long-term Debt$-67.1M
    ✗LynchPositive preferred
    LT Debt / Total Assets Change14.80% -> 11.11%
    ✓PiotroskiDecreased YoY
    Current Assets / Current Liabilities6.04
    ✓Dreman> 1.5✓SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.45
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Interest Coverage & Debt/EBITDAIC=22.8x, D/EBITDA=0.8x
    ✓MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.45
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.4466; #2358/4210 (top 56.0%)
    ✗AsnessTop 30% of eligible cross-section
  • Efficiency63% pass✓ 7✗ 4▾

    5 of 8 pass — Buffett, Piotroski and Akre object

    Current Ratio6.04
    ✓Graham>= 2.0
    ROIC (3-5 yr avg)-52.9%
    ✗Buffett> 10%
    ROIC - WACC-62.9%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)56.5%
    ✓Greenblatt> 25%
    Current Ratio Change YoY5.97 -> 6.71
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY0.87x -> 0.82x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities6.04
    ✓Dreman> 1.5
    Return on Invested Capital30.0%
    ✓Munger> 15%
    ROIC (high and growing)FY2023: ROIC=unavailable; FY2024: ROIC=26.1%; FY2025: ROIC=27.5%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROIC27.5% (RR=100% x ROIC=27.5%)
    ✓AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)2/2 years above 12% (latest 27.5%)
    ✓SleepROIC > 12% in a majority of years

Where It Falls Short

  • Valuation models0% pass✗ 8▾

    ADMA overvalued: all 8 models price fair value below $13.68 (median $4.71)

    Graham fair value$5.21
    ✗Graham-162.6% margin vs $13.68
    Buffett fair value$7.13
    ✗Buffett-91.9% margin vs $13.68
    Greenblatt fair value$3.91
    ✗Greenblatt-249.9% margin vs $13.68
    Dreman fair value$6.40
    ✗Dreman-113.8% margin vs $13.68
    Munger fair value$4.00
    ✗Munger-242.0% margin vs $13.68
    Pabrai fair value$10.28
    ✗Pabrai-33.1% margin vs $13.68
    Ackman fair value$4.20
    ✗Ackman-225.7% margin vs $13.68
    Templeton fair value$1.32
    ✗Templeton-936.4% margin vs $13.68
  • Valuation8% pass✓ 3✗ 25▾

    12 of 13 flag ADMA's valuation — Graham, Lynch, Greenblatt +9 more

    Net income / market capitalization+6.01%; #1413/6340 (top 22.3%)
    ✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Price / 3-yr avg EPS32.1x
    ✗Graham<= 15x
    Price-to-Book Ratio6.8x
    ✗Graham<= 1.5x
    P/E x P/B217.80
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)P/E 22.8x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value7.8%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=7.8%, ROC=56.5%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS22.8x
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)64.3x
    ✗Dreman< 8x
    Price / Book Value per Share6.8x
    ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessP/E=22.8x, OE Yield=4.1%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldP/E=22.8x, FCF Yield=0.9%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/E=22.8x, P/B=6.8x
    ✗MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic Value-113.8% (IV=$6.40 vs Price=$13.68)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share116.6x
    ✗Ackman<= 25
    Price vs. Trailing Low152% of trailing low ($9.01)
    ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
    Positive book equity / market capitalization+0.1445; #4505/6449 (top 69.9%)
    ✗AsnessTop 30% of eligible cross-section
    Price / Diluted EPS22.8x
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per Share6.85x
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change+139.4%
    ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+0.1711; #3923/5247 (top 74.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization+4.38%; #1713/4519 (top 37.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date+41.03%; #793/6202 (top 12.8%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Growth13% pass✓ 4✗ 9▾

    7 of 8 flag ADMA's growth — Graham, Lynch, Dreman +4 more

    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)P/E 22.8x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 35.3% vs Rev: 6.3%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction$-16.72 (2011) -> $0.60 (2025)
    ✓DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency2/15 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth65.2%
    ✓Ackman>= 5%
    Positive EPS Growth Frequency4/5 years with positive EPS growth
    ✓AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 34.4% -> 57.4%, operating margin 8.4% -> 37.5%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR64.6%
    ✓SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Profitability19% pass✓ 14✗ 21▾

    13 of 16 flag ADMA's profitability — Graham, Buffett, Lynch +10 more

    Net income / market capitalization+6.01%; #1413/6340 (top 22.3%)
    ✓AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
    Positive EPS (10 years)2/17 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)N/A (negative base EPS)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)2/17 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-5.5%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)37.5% (latest)
    ✓BuffettStable or rising over 10 years
    Free Cash Flow Proxy$143.0M
    ✓BuffettPositive and growing
    Earnings Variance (10-yr CoV)N/A (negative mean EPS)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)P/E 22.8x (growth N/A)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE41.6%
    ✓Lynch> 15%
    EBIT / Enterprise Value7.8%
    ✗Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=7.8%, ROC=56.5%
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets23.54%
    ✓PiotroskiROA > 0
    ROA Change YoY40.45% -> 23.54% (delta: -16.91%)
    ✗PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=8.07%, ROA=23.54%
    ✗PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY51.5% -> 57.4%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue45.2%
    ✓Dreman>= 8%
    Net Income / Shareholders' Equity41.6%
    ✓Dreman> 12%
    Margin of SafetyP/E=22.8x, P/B=6.8x
    ✗PabraiP/B < 1.5 or P/E < 15
    Return on Equity22.2% (3-yr avg)
    ✓AkreROE > 20% (3-year avg)
    Discount to Intrinsic Value-113.8% (IV=$6.40 vs Price=$13.68)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency2/15 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue46.5%
    ✓Ackman>= 15%
    Net Income / Shareholders Equity41.6%
    ✓Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend8.4% (2023) -> 37.5% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 34.4% -> 57.4%, operating margin 8.4% -> 37.5%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Gross profit / total assets+48.57%; #697/3702 (top 18.8%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity+41.60%; #275/5226 (top 5.3%)
    ✓AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.2558; #4464/5884 (top 75.9%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years2/10 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Cash Flow30% pass✓ 5✗ 7▾

    7 of 10 flag ADMA's cash flow — Piotroski, Dreman, Pabrai +4 more

    Free Cash Flow Proxy$143.0M
    ✓BuffettPositive and growing
    FCF Positive and Growing$132.9M
    ✓LynchPositive and growing
    Operating Cash Flow$50.4M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=8.07%, ROA=23.54%
    ✗PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)64.3x
    ✗Dreman< 8x
    P/E or FCF YieldP/E=22.8x, FCF Yield=0.9%
    ✗PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive3/15 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap4.1%
    ✓Ackman>= 4%
    Price / FCF per Share116.6x
    ✗Ackman<= 25
    Positive Operating Cash Flow frequency3/15 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$132.9M
    ✓Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization+4.38%; #1713/4519 (top 37.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Verdicts31% pass✓ 4✗ 9▾

    Split decision: 9 FAIL · 4 NEUTRAL · 2 BUY · 1 PASS

    Overall verdict
    ✗GrahamFAIL (3/9)✗BuffettFAIL (3/9)✗LynchFAIL (2/7)✓GreenblattRank #314•PiotroskiNEUTRAL (F-Score 6)✓DremanPASS (6/11)✓MungerBUY (4/4)✗PabraiFAIL (0/3)•AkreNEUTRAL (4/6)✗MarksFAIL (1/5)✓AckmanBUY (8/9)✗TempletonFAIL (3/8)•SleepNEUTRAL (4/6)✗AsnessFAIL (Rank #1394/2370 (Top 58.8%))✗NeffFAIL (2/6)✗SchlossFAIL (3/7)•OshaughnessyNEUTRAL (Not ranked)

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Pharmaceutical Products
SIC Sector: Chemicals & Pharmaceuticals
Size: Mid Cap($3.0B)
Revenue: $510.2M+19.6% YoY
Net Income: $146.9M-25.7% YoY

Financial Snapshot

Operating Margin37.5%
Return on Equity30.8%
Debt / Equity0.15
Current Ratio6.71
EPS (Diluted)$0.60−25.9% 1y
Buybacks (1y)$31.9M
Buybacks (2y)$31.9M
Shares Retired0.0% / −3.9% 2y

Similar Companies

MRKMerck & Co., Inc.
$364.3B
ABTABBOTT LABORATORIES
$188.0B
BMYBRISTOL MYERS SQUIBB CO
$129.7B
TECHBIO-TECHNE Corp
$11.4B

Shareholder Return

Fiscal 2025

Retired 0.0% of shares last year, 3.9% issued over two.

Buybacks
$31.9M
Dividends
—

What drove EPS

A buyback raises earnings per share without the company earning more. This splits each year's change into the two.

FY25
−25.9% = −25.7% + −0.3%
Earnings Fewer shares More shares

Share count is the denominator the filer used for diluted EPS, recovered as net income ÷ EPS — not the balance-sheet count, which is a point-in-time figure and would put the timing difference into this split. Years with a loss are omitted: a smaller share count makes a loss per share larger, so the decomposition inverts.

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex, buybacks.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, buybacks.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, capex, buybacks.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-02-25
FY 2024
Sources
  • 10-K · 2025-03-18
FY 2023
Sources
  • 10-K · 2024-02-28
FY 2022
Sources
  • 10-K · 2023-03-23
FY 2021
Sources
  • 10-K · 2022-03-24
Market Cap$3.0Bcurrent------$4.1Best.$3.8Best.$1.2Best.$819.8Mest.$284.1Mest.
Revenue$519.2M↑6%$141.1M↑5%$124.4M↑2%$114.5M$510.2M↑20%$426.5M↑65%$258.2M↑68%$154.1M↑90%$80.9M
Operating Income$241.2M↑44%$67.8M↑33%$52.4M↑23%$58.3M↑67%$191.4M↑38%$139.0M↑542%$21.6M↑155%-$39.4M↑33%-$58.4M
Net Income$182.4M↓13%$49.9M↑37%$37.8M↑11%$45.3M↑68%$146.9M↓26%$197.7M↑800%-$28.2M↑57%-$65.9M↑8%-$71.6M
EPS (Diluted)--$0.22↑47%$0.16↑14%$0.19↑73%$0.60↓26%$0.81↑723%$-0.13↑61%$-0.33↑35%$-0.51
Gross Margin68.5%↑25%70.8%↑26%69.4%↑26%70.5%↑33%57.4%↑11%51.5%↑49%34.4%↑50%22.9%↑1479%1.4%
Operating Margin46.5%↑36%48.0%↑26%42.2%↑20%50.9%↑68%37.5%↑15%32.6%↑289%8.4%↑133%-25.5%↑65%-72.1%
ROE41.6%↓14%———30.8%↓46%56.6%↑371%-20.9%↑52%-43.4%↑15%-50.8%
Total Debt$195.9M↑170%$195.9M↑170%$196.6M$196.9M$72.1M$72.3M------
Shareholders' Equity$438.5M↑2%$438.5M↑2%$408.2M↑2%$390.3M↑5%$477.3M↑37%$349.0M↑158%$135.2M↓11%$152.0M↑8%$141.2M
Current Ratio6.04↓15%6.04↓15%6.97↑31%6.95↑6%6.71↑12%5.97↑16%5.16↓25%6.896.87
Debt / Equity0.45↑166%0.45↑166%0.480.500.15↓27%0.21———
Operating Cash Flow$140.8M↑117%$17.4M↑31%$29.5M↑40%$58.2M↑396%$50.4M↓58%$118.7M↑1249%$8.8M↑115%-$59.5M↑47%-$112.4M
Free Cash Flow$132.9M↑226%$15.4M↑1529%$27.3M↑46%$55.7M↑329%$27.8M↓75%$110.4M↑2641%$4.0M↑105%-$73.4M↑42%-$125.9M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Pharmaceutical Products

ADMA vs Peers — Financial Grading

Revenue$510.2MBottom 25%
Net Income$146.9MMedian
ROE30.8%Top 25%
D/E0.15Top 25%
Op. Margin37.5%Top 25%
Curr. Ratio6.71Top 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
Merck & Co., Inc.MRK$364.3B$147.76$65.0B$18.3B34.7%0.94—1.542/95/94/70/3F-Score 41/11
ABBOTT LABORATORIESABT$188.0B$108.52$44.3B$6.5B12.5%0.2518.2%1.583/94/92/71/3F-Score 53/11
BRISTOL MYERS SQUIBB COBMY$129.7B$63.43$48.2B$7.1B38.2%2.4419.4%1.262/91/93/71/3F-Score 85/11
BIO-TECHNE CorpTECH$11.4B$72.80$1.2B$73.4M3.8%—8.4%3.464/93/93/70/3F-Score 54/11
REPLIGEN CORPRGEN$10.7B$167.79$738.3M$48.9M2.3%0.267.5%8.373/92/93/70/3F-Score 75/11
IONIS PHARMACEUTICALS INCIONS$4.8B$29.06$943.7M$381.4M-78.0%3.60-40.4%3.833/91/91/70/3F-Score 43/11
NEOGEN CORPNEOG$2.5B$11.23$870.4M$7.9M-0.4%0.76-2.5%3.823/91/92/70/3F-Score 64/11
Pharvaris N.V.PHVS$2.4B$33.36—$206.4M-64.8%0.00——0/90/92/70/3F-Score 22/11